容积旋转调强放疗联合计算机断层扫描引导自适应近距离放疗治疗局部晚期宫颈癌的安全性与疗效:单中心经验
该单中心回顾性研究分析了102例接受容积旋转调强放疗(VMAT)联合CT引导自适应近距离放疗(CTGAB)的局部晚期宫颈癌患者,中位随访19个月,2年与3年总生存率分别为89.6%和83%,≥3级胃肠道与泌尿毒性分别为4.9%和0.98%,作者认为该联合方案有效且安全。
要点
- 102例局部晚期宫颈癌接受VMAT联合CTGAB,中位随访19个月。
- 2年与3年总生存率分别为89.6%和83%,局部控制率分别为90.1%和79.3%。
- ≥3级胃肠道与泌尿毒性分别为4.9%和0.98%,≥4级胃肠道毒性为1.96%。
核心结论
- 作者认为VMAT联合CTGAB治疗局部晚期宫颈癌是一种有效且安全的方法,局部控制、总生存、无进展生存令人满意,毒性可接受。
研究设计与样本
- 单中心回顾性分析102例接受VMAT和CTGAB的局部晚期宫颈癌患者。
- 采用Kaplan-Meier法计算局部控制(LC)、总生存(OS)和无进展生存(PFS)。
- 肿瘤反应按RECIST 1.1评价,毒性按CTCAE 5.0评价胃肠道、泌尿和血液学毒性。
主要发现
- 中位随访19个月,完全缓解68例(66.7%)、部分缓解24例(23.5%)、疾病稳定4例(3.92%)、疾病进展6例(5.88%)。
- 2年和3年OS分别为89.6%和83%,2年和3年PFS分别为84.2%和74.3%,2年和3年LC分别为90.1%和79.3%。
- 直肠、膀胱、结肠和小肠的平均累积D2cm3分别为78.07(SD:0.46)Gy、93.20(SD:0.63)Gy、63.55(SD:1.03)Gy和61.07(SD:0.75)Gy。
- 高危临床靶区(HR-CTV)的平均累积D90%为92.26(SD:0.35)Gy。
- ≥3级胃肠道和泌尿毒性发生率分别为4.9%和0.98%,1.96%的患者观察到≥4级胃肠道毒性,无患者观察到≥4级泌尿毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Volumetric modulated arc therapy (VMAT) is a novel form of IMRT, which can deliver more accurate dose distribution and shorten treatment time. Compared to MRI-guided adaptive brachytherapy, which is recommended as gold standard imaging for cervical cancer contours, CT-guided adaptive brachytherapy (CTGAB) is more available, more widespread, and more affordable in many centers. This study aims to retrospectively analyze the efficacy and the safety of VMAT combined with CTGAB for patients with locally advanced cervical cancer. METHODS AND MATERIALS: This study retrospectively analyzed 102 patients with locally advanced cervical cancer who underwent VMAT and CTGAB. Clinical outcomes including local control (LC), overall survival (OS) and progression-free survival (PFS), tumor response to treatment evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1), and toxicities including gastrointestinal toxicity, urinary toxicity and hematologic toxicity evaluated by the Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) were analyzed. The Kaplan-Meier method was used to calculate LC, OS, and PFS. RESULTS: Median follow-up time was 19 months. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) occurred in 68 (66.7%), 24 (23.5%), 4 (3.92%), and 6 (5.88%), respectively. The 2-year and 3-year OS were 89.6% and 83%, respectively. The 2-year and 3-year PFS were 84.2% and 74.3%, respectively. The 2-year and 3-year LC were 90.1% and 79.3%, respectively. The average cumulative D2cm3 in the rectum, the bladder, the colon, and the small intestine were 78.07 (SD: 0.46) Gy, 93.20 (SD: 0.63) Gy, 63.55 (SD: 1.03) Gy and 61.07 (SD: 0.75) Gy, respectively. The average cumulative D90% of the high-risk clinical target volume (HR-CTV) was 92.26 (SD: 0.35) Gy. Grade ≥ 3 gastrointestinal and urinary toxicities occurred in 4.9% and 0.98%, respectively. 1.96% of patients were observed grade ≥ 4 gastrointestinal toxicities and none of the patients observed grade ≥ 4 urinary toxicities. CONCLUSION: VMAT combined with CTGAB for locally advanced cervical cancer was an effective and safe treatment method, which showed satisfactory LC, OS, PFS, and acceptable toxicities.
引用
- Yang T, Zhao T, Ji Z, et al. The safety and efficacy of volumetric modulated Arc therapy combined with computer tomography-guided adaptive brachytherapy for locally advanced cervical cancer: a single institution experience. Radiat Oncol. 2024. PMID: 38909242. doi:10.1186/s13014-024-02476-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。